Cascadian Therapeutics Reports Third Quarter 2016 Financial Results and Provides Corporate Update
07 nov. 2016 16h05 HE
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today provided third quarter highlights and reported financial results...
Cascadian Therapeutics Announces Presentation of Tucatinib in Combination Therapy in Patients with Cutaneous HER2+ Metastatic Breast Cancer
10 oct. 2016 07h10 HE
|
Cascadian Therapeutics
SEATTLE, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced the presentation of clinical activity of tucatinib, its...
Cascadian Therapeutics Announces Proposal for Reverse Stock Split
04 oct. 2016 16h11 HE
|
Cascadian Therapeutics
SEATTLE, Oct. 04, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that its board of directors has approved a plan for a...
Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress
28 sept. 2016 08h00 HE
|
Cascadian Therapeutics
SEATTLE, Sept. 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib...
Cascadian Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare Conference
20 sept. 2016 08h00 HE
|
Cascadian Therapeutics
SEATTLE, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will...
Cascadian Therapeutics to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
06 sept. 2016 08h00 HE
|
Cascadian Therapeutics
SEATTLE, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Scott Myers, President and CEO, and Luke Walker,...
Cascadian Therapeutics Announces Approval of Nonproprietary Name “tucatinib” for Lead Product Candidate ONT-380
31 août 2016 16h02 HE
|
Cascadian Therapeutics
SEATTLE, Aug. 31, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the United States Adopted Names (USAN) Council and...
Cascadian Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update
08 août 2016 16h02 HE
|
Cascadian Therapeutics
Reported positive interim results from Phase 1b “Triplet” study investigating ONT-380 in combination with trastuzumab and capecitabinePhase 2 “HER2CLIMB” study enrolling patientsSEATTLE, Aug. 08,...
Cascadian Therapeutics Receives ONT-380 Fast Track Designation from FDA for the Treatment of Advanced HER2+ Metastatic Breast Cancer
29 juin 2016 08h00 HE
|
Cascadian Therapeutics
SEATTLE, June 29, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that the ONT-380 program in advanced HER2+ metastatic...
Cascadian Therapeutics Announces Exercise of Underwriters' Over-Allotment Option and Closing of $46.0 million Concurrent Offerings of Common Stock and Series D Convertible Preferred Stock
28 juin 2016 16h01 HE
|
Cascadian Therapeutics
SEATTLE, June 28, 2016 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC) today announced that it has closed the previously announced underwritten public offering of 40,250,000 shares...